Alimera Sciences Stock
Your prediction
Pros and Cons of Alimera Sciences in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alimera Sciences vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alimera Sciences | - | - | - | - | - | - | - |
| Rockwell Medical Inc. | 0.320% | -14.198% | 28.065% | -53.089% | 33.555% | -42.452% | -92.251% |
| Pacira Pharmaceuticals | 0.610% | 4.242% | -20.370% | -27.731% | -20.370% | -51.136% | -69.286% |
| Twist Bioscience Corp | 1.040% | -0.366% | 23.329% | -28.904% | 27.181% | 37.955% | -73.368% |
Comments
Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat
Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat
Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat